{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:53:55Z","timestamp":1758819235003,"version":"3.41.2"},"reference-count":17,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/igc.0b013e31822265e7","type":"journal-article","created":{"date-parts":[[2011,6,30]],"date-time":"2011-06-30T14:29:57Z","timestamp":1309444197000},"page":"1479-1485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["The Relationship Between ERCC1 Expression and Clinical Outcome in Patients With FIGO Stage I to Stage II Uterine Cervical Adenocarcinoma"],"prefix":"10.1016","volume":"21","author":[{"given":"Kiyoshi","family":"Hasegawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rina","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Torii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuko","family":"Oe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Udagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/IGC.0b013e31822265e7_bb0005","first-page":"2286","article-title":"Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer","volume":"8","author":"Lord","year":"2002","journal-title":"Clin Cancer Res."},{"key":"10.1097\/IGC.0b013e31822265e7_bb0010","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/j.1349-7006.2007.00557.x","article-title":"Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy","volume":"98","author":"Azuma","year":"2007","journal-title":"Cancer Sci."},{"key":"10.1097\/IGC.0b013e31822265e7_bb0015","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","article-title":"DNA repair by ERCC1 in non-small-lung cancer and cisplatin-based adjuvant chemotherapy","volume":"355","author":"Olaussen","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1097\/IGC.0b013e31822265e7_bb0020","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1200\/JCO.1998.16.1.309","article-title":"ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy","volume":"16","author":"Metzger","year":"1998","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e31822265e7_bb0025","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejca.2007.09.006","article-title":"ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer","volume":"44","author":"Kim","year":"2008","journal-title":"Eur J Cancer."},{"key":"10.1097\/IGC.0b013e31822265e7_bb0030","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/annonc\/mdl435","article-title":"Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy","volume":"18","author":"Bellmunt","year":"2007","journal-title":"Ann Oncol."},{"key":"10.1097\/IGC.0b013e31822265e7_bb0035","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/IGC.0b013e3181a12e09","article-title":"The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer","volume":"19","author":"Steffensen","year":"2009","journal-title":"Int J Gynecol Cancer."},{"key":"10.1097\/IGC.0b013e31822265e7_bb0040","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ygyno.2010.07.018","article-title":"Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma","volume":"119","author":"Scheil-Bertram","year":"2010","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31822265e7_bb0045","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/1097-0215(20000920)89:5<453::AID-IJC9>3.0.CO;2-E","article-title":"ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells","volume":"89","author":"Britten","year":"2000","journal-title":"Int J Cancer."},{"key":"10.1097\/IGC.0b013e31822265e7_bb0050","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ygyno.2010.10.034","article-title":"ERCC1 (excision repair cross-complementation group 1) expression as a predictor for response of neoadjuvant chemotherapy for FIGO 2B uterine cervix cancer","volume":"120","author":"Park","year":"2011","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31822265e7_bb0055","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.2006.09.7915","article-title":"Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer","volume":"25","author":"Cobo","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e31822265e7_bb0060","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/00130404-200309000-00013","article-title":"The role of chemotherapy in the management of carcinoma of the cervix","volume":"9","author":"Thigpen","year":"2003","journal-title":"Cancer J."},{"key":"10.1097\/IGC.0b013e31822265e7_bb0065","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/0090-8258(92)90251-D","article-title":"A randomized trial of adjuvant chemotherapy after radical hysterectomy in stage Ib-IIa cervical cancer patients with pelvic lymph node metastasis","volume":"46","author":"Tattersall","year":"1992","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31822265e7_bb0070","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ygyno.2006.04.019","article-title":"Treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate- and high-risk stage IB-IIA cervical cancer","volume":"103","author":"Takeshima","year":"2006","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31822265e7_bb0075","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1006\/gyno.1999.5343","article-title":"Chemotherapy versus radiotherapy versus observation for high-risk cervical carcinoma after radical hysterectomy: a randomized, prospective, multicenter trial","volume":"73","author":"Lahousen","year":"1999","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31822265e7_bb0080","article-title":"A randomized phase III trial of four cisplatin containing doublet combination in stage IVB, recurrent or persistent cervical carcinoma: a Gynecologic Oncology Group study","author":"Monk","year":"2008","journal-title":"ASCO Proc"},{"key":"10.1097\/IGC.0b013e31822265e7_bb0085","first-page":"S43","article-title":"FIGO: 26th volume of the annual reports on the results of treatment in gynecological cancer","volume":"95","author":"Quinn","year":"2006","journal-title":"Int J Gynecol Obstet."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24046097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24046097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.lww.com\/ijgc\/Fulltext\/10.1097\/IGC.0b013e31822265e7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:18:09Z","timestamp":1753233489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24046097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S1048891X24046097"],"URL":"https:\/\/doi.org\/10.1097\/igc.0b013e31822265e7","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2011,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Relationship Between ERCC1 Expression and Clinical Outcome in Patients With FIGO Stage I to Stage II Uterine Cervical Adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1097\/IGC.0b013e31822265e7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright Copyright \u00a9 2011 by IGCS and ESGO.","name":"copyright","label":"Copyright"}]}}